NCT02730247View on ClinicalTrials.gov

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 5, 2017

Primary Completion Date

September 8, 2019

Study Completion Date

September 8, 2019

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

ramucirumab

it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.

DRUG

nab-paclitaxel

it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Liza Villaruz, MD

OTHER

NCT02730247 - Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter